







































EGF = epidermal growth factor; Erk = extracellular signal-related kinase; IL = interleukin; MAPK = mitogen-activated protein kinase; NRG = neureg-
ulin; PTB = phosphotyrosine binding; RTK = receptor tyrosine kinase; SH2 = Src homology 2.
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Introduction
Ligand binding to ErbB receptors results in dimerization
and activation of their intrinsic kinase activity followed by
phosphorylation of specific tyrosine residues in the recep-
tor cytoplasmic tails. These phosphorylated tyrosines, in
turn, provide recognition sites for intracellular signaling
intermediates, which link receptor tyrosine kinases (RTKs)
to downstream transduction cascades [1]. The selection
and combination of pathways activated ultimately result in
changes in gene expression, thereby triggering the appro-
priate biological response to the extracellular cues
received. Driven by the binding specificities of the bivalent,
epidermal growth factor (EGF)-related peptide ligands and
the complement of receptors available on the cell, ErbB
receptors form different homodimeric and heterodimeric
complexes (see review by Gullick [2]). Essentially, all pair-
wise combinations of the four receptors can be induced by
the 10 specific ErbB ligands characterized to date, gener-
ating a great potential for signal diversification. Alterna-
tively, receptor overexpression that has been observed in
various tumors, including those of the breast, promotes
spontaneous receptor dimerization in the absence of a
ligand and constitutive receptor activation [3].
It has become apparent that all RTKs funnel their signals
through generic cellular pathways, yet they participate in
mediating distinct biological programs. Therefore, how
signaling specificity of different RTKs and ErbB receptors
in particular is achieved has become an area of intense
research.
Review
Update on HER-2 as a target for cancer therapy
Intracellular signaling pathways of ErbB2/HER-2 and family
members
Monilola A Olayioye
The Walter and Eliza Hall Institute of Medical Research, The Royal Melbourne Hospital, Victoria, Australia
Correspondence: Monilola A Olayioye, The Walter and Eliza Hall Institute of Medical Research, PO The Royal Melbourne Hospital, Victoria 3050,
Australia. Tel: +61 3 9342 8636; fax: +61 3 9342 8634; e-mail: olayioye@wehi.edu.au
Abstract
ErbB (also termed HER) receptors are expressed in various tissues of epithelial, mesenchymal and
neuronal origin, in which they are involved in the control of diverse biological processes such as
proliferation, differentiation, migration and apoptosis. Furthermore, their deregulated expression has
been implicated in many types of human cancers and is associated with poor clinical prognosis. Owing
to the importance of ErbB proteins in both development and cellular transformation, a lot of attention
has been drawn to the intracellular signals initiated by the engagement of this family of receptor
tyrosine kinases. This review will focus on the membrane proximal events triggered by the ErbB
receptor network and will address questions of how receptor heterodimerization may contribute to
signal specification and diversification.
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ErbB receptors and their cytoplasmic partners
The pattern and the sequence context of phosphorylated
tyrosines on the ErbB receptor determine the subset of
Src homology 2 (SH2) and phosphotyrosine binding
(PTB) domain-containing molecules recruited and, conse-
quently, the downstream pathways activated. SH2
domains are protein modules of about 100 amino acids
that recognize phosphorylated tyrosines in the context of
three to six carboxy-terminal amino acids. In contrast to
SH2 domains, interaction of PTB domains (which are
approximately 150 amino acids in length) is determined by
the residues preceding the phosphorylated tyrosine [4].
Apart from docking sites generated by receptor autophos-
phorylation, cytoplasmic kinases such as Src can phos-
phorylate additional carboxy-terminal tyrosines on the
receptor, thereby creating even more potential interaction
sites for cytosolic signaling intermediates [5,6].
Known SH2 and PTB domain-containing proteins that
interact with ErbB receptors include the adaptor proteins
Grb2, Grb7, Shc, Crk, and Gab1, protein and lipid
kinases such as Src and phosphatidylinositol 3-kinase,
phospholipase Cγ, and protein phosphatases such as
SHP1 and SHP2 (Fig. 1). A great deal of overlap exists
among the subsets of signaling proteins that associate
with each of the receptors. However, one example of pref-
erential binding is the ubiquitin ligase Cbl, which is an
exclusive partner for ErbB1 [7]. Furthermore, of the four
receptors, only ErbB3 efficiently induces phosphatidyl-
inositol 3-kinase due to multiple coupling sites for its regu-
latory subunit p85 [8].
Apart from ligand-controlled recruitment of specific phos-
photyrosine-binding signaling molecules, the integrity of
ErbB signaling also requires phosphorylation-independent
assembly with protein partners that regulate receptor activ-
ity and correct membrane localization. Employing yeast two-
hybrid screens, several ErbB interactors that fulfill such
functions have recently been identified (Fig. 1). For example,
the immediate early gene 33 (now termed receptor-associ-
ated late transducer) was reported to bind to activated
ErbB2 and to inhibit ErbB2 mitogenic signaling by a nega-
tive feedback mechanism [9]. In addition, the postsynaptic
density protein PSD-95, a PDZ domain-containing protein
known to aid in receptor scaffolding, interacts primarily with
ErbB4 at neuronal synapses where it enhances neuregulin
(NRG)-induced kinase activity [10,11]. Finally, the novel
PDZ member, Erbin, couples specifically to ErbB2 and is
crucial for restriction of the receptor to the basolateral mem-
brane of epithelial cells [12].
Biological outcomes of receptor activation
Although binding specificities of the receptor autophos-
phorylation sites have been assessed, delineation of the
functions of individual phosphorylated tyrosines and their
relative contribution to specific biological outcomes is still
at an early stage. One way to address this issue is by
analysis of mutant receptor proteins in which only a single
Figure 1
ErbB receptors and their cytoplasmic partners. The interaction of various proteins containing Src homology 2 and phosphotyrosine binding
domains has been mapped to specific ErbB carboxy-terminal tyrosines. Autophosphorylation sites are shown in red, interaction sites demonstrated
by phosphopeptide competition analyses are in black, and sites identified as Src phosphorylation sites are in blue. The receptor-associated late







































tyrosine phosphorylation site has been retained. Trans-
genic nematodes expressing such mutants of the
Caenorhabditis elegans ErbB ortholog Let23 revealed
that individual tyrosines contribute to distinct biological
programs. While the presence of any of three tyrosines is
sufficient for viability and vulval differentiation, fertility is
conferred by one specific tyrosine that does not rescue
the other Let23 functions [13].
In a study using the activated Neu (rat ErbB2 containing a
transmembrane point mutation that leads to spontaneous
dimerization and, thus, receptor activation) as a model,
mutation of all the tyrosine autophosphorylation sites
resulted in dramatic reduction of its transforming potential
in NIH3T3 focus assays. Restoration of any of four
tyrosines rescued the oncogenic properties of the recep-
tor, suggesting that Neu induces transformation through
multiple functionally redundant tyrosine phosphorylation
sites [14]. However, mammary tumors induced by expres-
sion of two of these Neu mutants in transgenic mice
revealed differences in the capacity of the tumors to
metastasize [15]. Based on in vitro data, both mutants are
believed to signal primarily through the mitogen-activated
protein kinase (MAPK) pathway. These in vivo studies
clearly demonstrate that there are functional differences
between the individual tyrosine phosphorylation sites.
Investigation of the signaling properties of tyrosines on
wild-type ErbB2 and other ErbB members, stimulated in a
ligand-dependent fashion, should provide further insight
into how signal specification may be linked to individual
receptor phosphorylation sites.
The signaling potential of ErbB2
Overexpression of ErbB2 in cell lines leads to transforma-
tion in the absence of a ligand [16]. None of the EGF family
of ligands binds to ErbB2 directly. Therefore, in a technical
sense, ErbB2 remains an orphan receptor. It appears,
however, due to ErbB2 being the preferred dimerization
partner for all other ErbB receptors [17], that ErbB2 mainly
functions as a shared coreceptor (Fig. 2). Indeed, more
than 10 years ago, coexpression of ErbB2 with ErbB1 was
shown to synergize in transforming NIH3T3 fibroblasts
[18]. It has now emerged as a general theme that ErbB
receptors cooperate in in vitro cellular transformation as
well as in vivo in human tumors. For example, in breast
cancer, upregulation of ErbB1 and ErbB3 has been
observed along with ErbB2 overexpression.
How does ErbB2 modulate signaling and contribute to
transformation? Several approaches, such as antisense-
mediated and ribozyme-mediated downregulation of ErbB2
or blockade of receptor function with monoclonal antibod-
ies, have demonstrated cellular dependence on this recep-
tor for maintenance of the transformed phenotype. The
design of an ErbB2-specific intracellular single-chain anti-
body that captures the receptor in the endoplasmic reticu-
lum, leading to its functional inactivation [19], has proven a
useful tool to address this question in more detail. Inducible
expression of this single-chain antibody in the ErbB2 over-
expressing breast carcinoma cell line SKBR3 led to accu-
mulation of cells in the G1 phase of the cell cycle as a result
of reduction of Cdk2 activity due to increased association
with the Cdk inhibitor p27 [20]. This was accompanied by
loss of ErbB3 tyrosine phosphorylation, demonstrating that
the functional ErbB signaling unit in these cells is the
ErbB2/ErbB3 heterodimer. Not only basal growth of
SKBR3 cells, but also ligand-induced proliferation of several
breast cancer lines expressing moderate levels of ErbB2
was decreased when the receptor was similarly downregu-
lated [21,22]. The presence of ErbB2 was also shown to
enhance ligand-stimulated invasion of the extracellular
matrix [23], thereby extending the transforming properties of
ErbB2-containing dimers even further.
Both EGF, which binds ErbB1, and the ErbB3/ErbB4-
binding ligand NRG displayed, at the molecular level, higher
ligand affinity towards ErbB2-containing heterodimers
owing to a decelerated off-rate [24]. This could be corre-
lated with potentiation and prolongation of MAPK and
p70S6K signaling pathways in cells expressing ErbB2 [22].
ErbB receptor heterodimerization not only leads to signal
amplification, but also results in signal diversification. It
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Figure 2
Heterodimerization modulates ErbB signaling. Ligand binding triggers
ErbB dimerization and kinase activation, leading to phosphorylation of
carboxy-terminal tyrosine residues in trans. When ErbB2 is expressed,
mainly ErbB2-containing heterodimers are formed that, when
compared with their homodimeric counterparts, possess altered
signaling properties. EGF, epidermal growth factor; NRG, neuregulin;
P, phosphotyrosine. appears that the signal elicited by a receptor heterodimer
is not simply the sum of the signaling properties of the
individual dimerization partners. For example, IL3-depen-
dent BaF/3 cells engineered to coexpress ErbB1 and
ErbB4 demonstrate IL3-independent proliferation in the
presence of NRG or EGF. However, neither ligand pro-
motes IL3-independent proliferation of cells that
expressed ErbB1 or ErbB4 alone [25]. Likewise, activa-
tion of Stat transcription factors does not occur in cells
expressing ErbB2 or ErbB4 but is triggered downstream
of the NRG-induced ErbB2/ErbB4 heterodimer [26].
The initial observation that the Cbl protein couples only to
EGF-activated ErbB1 but not to ErbB1 transactivated by
NRG-induced heterodimerization with ErbB3 or ErbB4
[17] suggested that the phosphorylation pattern on a
given receptor might be modulated by the dimerization
partner. To verify this hypothesis, NIH3T3 cells that
possess a low background of endogenous ErbB recep-
tors were used to generate lines expressing ErbB recep-
tors in single and pairwise combinations [27]. The Grb2
protein bound only to EGF-activated ErbB1 in this cellular
system, and not to NRG-activated ErbB1 in a heterodimer
with ErbB4. Moreover, despite similar levels of total phos-
photyrosine, the homodimerized point mutant of ErbB2
was considerably more potent in binding Shc than ErbB2
transactivated by EGF. Two-dimensional phosphopeptide
mapping of both ErbB1 and ErbB2 provided proof that
receptor phosphorylation was indeed modulated in trans
in a heterodimer. These studies have recently been
extended by the characterization of the signaling proper-
ties of ErbB4 homodimers stimulated with the ErbB4-
binding ligands betacellulin and several NRG isoforms.
Interestingly, recruitment of Shc, Grb2 and p85 molecules
to ErbB4 was promoted to a different extent by the individ-
ual ligands which could be correlated with differential
ErbB4 phosphorylation patterns [28]. Taken together, it
appears that both the activating ligand and the composi-
tion of the ErbB dimer induce conformational changes that
ultimately dictate the choice of carboxy-terminal tyrosines
transphosphorylated by the ErbB kinase domains.
Signaling kinetics
The cell employs several mechanisms to re-establish its
default settings after ligand-induced RTK activation. These
mechanisms include receptor dephosphorylation by tyro-
sine phosphatases, receptor desensitization by phospho-
rylation of specific serine and/or threonine residues and,
finally, receptor downregulation by internalization and sub-
sequent lysosomal degradation. ErbB1 is a prime example
of a receptor that is dramatically downregulated, which is
probably due to its interaction with eps15 and related pro-
teins that are involved in clathrin assembly, and its interac-
tion with the ubiquitin ligase Cbl that targets the receptor
for lysosomal degradation [29]. In contrast to ErbB1, all
other ErbB receptors were reported to be endocytosis
impaired [30]. Interestingly, ErbB2 coexpression was
shown to inhibit downregulation of activated ErbB1 by
increasing its rate of recycling [31,32]. Thus, receptor
dimerization of ErbB1 with ErbB2 may not only prolong
signaling by modulating ligand binding properties as dis-
cussed earlier, but also by altering receptor trafficking.
All the ErbB receptors, including the Drosophila and C.
elegans orthologs DER and Let23, activate the MAPK
pathway. Moreover, multiple tyrosines on a single ErbB
receptor are known to impinge on this signaling pathway,
via various signaling routes, prompting the question of
how signaling specificity is achieved. It has become
increasingly clear that duration and magnitude of a signal
are crucial parameters that act in specification of cellular
responses [33]. A well-described example is the neuronal
cell line PC12 in which nerve growth factor stimulates
sustained activation of extracellular signal-related kinase
(Erk) resulting in differentiation, whereas EGF transduces
a proliferative signal due to transient Erk activation.
In the breast carcinoma cell lines T47D and SKBR3, initial
EGF-induced and NRG-induced activation of the MAPK
pathway was found to require the cytoplasmic kinase Src
while late activation appeared to be directly mediated by
the receptors themselves [34]. Significantly, delayed acti-
vation kinetics of Erk as a result of Src kinase inactivation
suppressed transcription from an Erk-responsive pro-
moter, underscoring the importance of the exact timing of
the signal. The impact of differential signaling kinetics
emanating from ErbB receptors on transcription is illus-
trated by a recent study in which the breast carcinoma cell
line MDA-MB453 was stimulated with either NRG1 or
NRG2 [35]. In these cells, both ligands signal through an
ErbB2/ErbB3 heterodimer, leading to the activation of the
same subset of downstream pathways but with differing
signaling kinetics. Using gene expression profiling, it could
be shown that these differences in signaling magnitude
and duration translate into distinct responses at the trans-
criptome level.
Conclusion
The ability of ErbB receptors to form both homodimers
and heterodimers with distinct signaling properties in
response to a plethora of ErbB-specific ligands generates
a complex signaling network with an enormous potential
for signal amplification and diversification. Mapping of
intracellular pathways activated by this family of RTKs is
further complicated by the finding that ErbB receptors do
not act in isolation, but are integrated into signaling events
of other classes of receptors. For example, cellular
responses to EGF stimulation were modulated by the
extracellular matrix, presumably via crosstalk between inte-
grin receptors and ErbB1 [36]. The ultimate goal will be
the understanding of signaling in a specific cell type at a
given developmental stage. Recent advances in the field
Breast Cancer Research    Vol 3 No 6 Olayioyeof transcriptomics and proteomics have created technolo-
gies that may help in elucidating this issue by generating a
more global picture of signaling processes driven by ErbB
receptors and RTKs in general.
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